연구성과로 돌아가기
2022 연구성과별 연구자 정보 (1326 / 2879)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Lee, Joon Hyeok | Lee, JH | 12 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Koh, Kwang Cheol | Koh, KC | 13 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Paik, Seung Woon | Paik, SW | 14 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Park, Hee Chul | Park, HC | 15 | Sungkyunkwan Univ Sch Med, Dept Radiat Oncol, Samsung Med Ctr, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Kang, Tae Wook | Kang, TW | 16 | Sungkyunkwan Univ, Dept Radiol & Ctr Imaging Sci, Samsung Med Ctr, Sch Med, Seoul, South Korea | CAI-4750-2022 | Kan, Tae Wook | yh.paik@skku.edu;hoylim@skku.edu; | |||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Rhim, Hyunchul | Rhim, H | 17 | Sungkyunkwan Univ, Dept Radiol & Ctr Imaging Sci, Samsung Med Ctr, Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Lee, Su Jin | Lee, SJ | 18 | Ewha Womans Univ, Dept Internal Med, Div Hematol Oncol, Coll Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Cristescu, Razvan | Cristescu, R | 19 | Merck & Co Inc, Kenilworth, NJ USA | yh.paik@skku.edu;hoylim@skku.edu; | |||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Lee, Jeeyun | Lee, J | 20 | Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | C-9646-2011 | Lee, Jee | yh.paik@skku.edu;hoylim@skku.edu; | |||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Paik, Yong Han | Paik, YH | 21 | 교신저자 | Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | ||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Paik, Yong Han | Paik, YH | 21 | 교신저자 | Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | ||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Paik, Yong Han | Paik, YH | 21 | 교신저자 | Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea | yh.paik@skku.edu;hoylim@skku.edu; | ||||
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial | Lim, Ho Yeong | Lim, HY | 22 | 교신저자 | Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea | KBA-8868-2024 | Lim, Ho Yeong | yh.paik@skku.edu;hoylim@skku.edu; | ||
| Hepatoprotective Potential of Malaysian Medicinal Plants: A Review on Phytochemicals, Oxidative Stress, and Antioxidant Mechanisms | Venmathi Maran, Balu Alagar | Maran, BAV | 1 | Univ Malaysia Sabah, Borneo Marine Res Inst, Kota Kinabalu 88400, Sabah, Malaysia | G-5163-2014 | Venmathi Maran, Balu Alagar | 0000-0003-1090-5295 | Venmathi Maran, Balu Alagar | bavmaran@ums.edu.my;miqbal@ums.edu.my;prakashg@knu.ac.kr;abc2000@knu.ac.kr;pvrao@ums.edu.my;dawoodshah@ums.edu.my; | |
| Hepatoprotective Potential of Malaysian Medicinal Plants: A Review on Phytochemicals, Oxidative Stress, and Antioxidant Mechanisms | Iqbal, Mohammad | Iqbal, M | 2 | Univ Malaysia Sabah, Biotechnol Res Inst, Kota Kinabalu 88400, Sabah, Malaysia | bavmaran@ums.edu.my;miqbal@ums.edu.my;prakashg@knu.ac.kr;abc2000@knu.ac.kr;pvrao@ums.edu.my;dawoodshah@ums.edu.my; |
페이지 이동: